Total-Body CT Screening
Customize your policy alerts
Sign up for Aetna Policy 0603 alerts
Get alerted when Policy 0603 changes without checking for updates manually.
Monitor payer policy activity
This policy addresses the use and coverage stance for total-body (whole-body/full-body) CT screening and related ultrafast (electron-beam) CT screening, and applies to Aetna members and ordering providers.
No material clinical or coverage changes in this revision.
Coverage Criteria and Policy Position
inv-01: Experimental and Investigational
Not covered (experimental/investigational):
Policy statement.
inv-02: Trauma — selective coverage in high-risk patients
Evidence-based coverage considerations for total-body CT in trauma:
Based on REACT-2 trial and systematic reviews; subgroup findings limited by power.
inv-03: MGUS / Smoldering MM — coverage with risk stratification
Evidence-based coverage considerations for low-dose whole-body CT in plasma cell disorders:
Consistent with IMWG recommendations and UpToDate guidance; imaging may be omitted for low-risk MGUS (eg, IgG-type with M protein <1.5 g/dL and normal FLC ratio).
Aetna considers total-body (full-body/whole-body) CT screening and full-body ultrafast (electron-beam) CT screening experimental and investigational because these approaches have not been shown to be effective as screening tests. Evidence reviews note limited data on accuracy and cost-effectiveness and emphasize a high ratio of false-positive to true-positive findings, with no demonstrated improvement in clinical outcomes for asymptomatic, low-risk populations.
Routine whole-body CT screening is not recommended for asymptomatic, low-risk individuals, including those with low-risk MGUS without clinical concern for bone lesions. UpToDate guidance states imaging may be omitted for low-risk MGUS (e.g., IgG-type with serum M protein < 1.5 g/dL and a normal serum free light-chain ratio), and there are no data that total-body imaging improves outcomes in asymptomatic populations; therefore routine screening is excluded.
Screening asymptomatic, low-risk individuals with total-body CT is considered not medically necessary due to lack of evidence of benefit and potential harms including radiation exposure, a high rate of incidental and false-positive findings, downstream unnecessary testing or procedures, and associated costs.
Indiscriminate use of whole-body CT for general health screening in asymptomatic persons is not supported. Professional reviews advise against routine or indiscriminate application because of short-term risks (for example, contrast-related renal injury), long-term risks (radiation-induced cancer), high rates of false positives, and substantial cost.
When Imaging May Be Appropriate
inv-21: Trauma evaluation (contextual discussion, not a screening endorsement) — 1 top-level node
Contextual evaluation; not an endorsement for screening.
inv-22: Immediate total-body CT for severe trauma/high-risk patients — 1 top-level node
Apply selection based on clinical severity and suspicion for injuries requiring urgent intervention.
inv-23: Low-dose whole-body CT for MGUS/SMM work-up — 1 top-level node
Reflects IMWG and UpToDate recommendations.
Coding and Billing
| S8092 | Electron beam computed tomography (also known as ultrafast CT, cine CT) |
Provider Actions, Documentation, and Authorization
Prior authorization — not applicable for experimental/investigational TBCT
Aetna considers total-body (full-body/whole-body) CT screening and full-body ultrafast (electron-beam) CT screening experimental and investigational and therefore not a covered benefit; prior authorization will not make these experimental services payable.
Selective prior authorization recommended for iTBCT in non-severe trauma
Prior authorization is appropriate to ensure appropriate patient selection when immediate total-body CT (iTBCT) is considered for patients without documented severe trauma or clear indicators of multiple trauma/TBI, since benefit and cost-effectiveness are primarily supported in multiple trauma or TBI subgroups.
- Consider authorization when iTBCT is ordered for patients without documented severe injury or without indicators of multiple trauma or traumatic brain injury.
Document specific clinical indication for whole‑body imaging
Provide clinical justification that matches the intended use of whole-body imaging (e.g., specify suspected condition such as high-risk MGUS, smoldering MM, or the clinical suspicion of multiple trauma) and include relevant objective findings.
- Document the specific clinical indication prompting whole-body imaging.
- Include objective risk factors or exam findings that support use of WB-CT or iTBCT.
Stepwise imaging sequence for MGUS / SMM work-up
When evaluating patients for suspected smoldering multiple myeloma or high-risk MGUS, perform whole-body low-dose CT (WBLD-CT) or WB-CT/FDG-PET/CT first; if these studies are negative or inconclusive and clinical suspicion remains, proceed to whole-body MRI per IMWG recommendations.
- WB-CT or FDG-PET/CT as first-line imaging for suspected SMM or high-risk MGUS.
- If WB-CT / FDG-PET/CT is negative or inconclusive, obtain whole-body MRI next.
Documentation expectations — code and report details
Include HCPCS code S8092 where applicable (electron beam CT) and document findings and any recommendations resulting from screening or diagnostic whole-body imaging, noting that large screening series commonly report many incidental findings and follow-up recommendations.
- List HCPCS S8092 when electron-beam CT is performed.
- Document all significant imaging findings and any recommended additional evaluations.
Include clinical risk stratification and justification
Clinical documentation should include patient risk stratification and objective measures relevant to the indication (for example, MGUS risk level or laboratory cutoffs, trauma severity including GCS, or specific suspicion for multiple myeloma/bone disease).
- For MGUS: record risk features (e.g., M protein level, free light chain ratio) when applicable.
- For trauma: document severity indicators such as Glasgow Coma Scale or mechanism of injury.
- State the level of clinical suspicion for multiple myeloma or bone involvement.
Denial trigger — TBCT screening not covered
Requests for total-body CT screening or full-body ultrafast (electron-beam) CT screening for screening purposes will be denied as these services are considered experimental and investigational and are not covered.
Risks of indiscriminate whole‑body CT use
Be aware that indiscriminate use of whole-body CT is discouraged because of short-term risks (contrast-related renal injury), long-term risks (radiation-induced cancer), and high costs; overuse may lead to noncoverage decisions based on medical necessity.
- Balance the diagnostic need against risk of contrast nephrotoxicity in patients receiving contrast-enhanced studies.
- Consider radiation exposure and downstream costs when ordering whole-body CT.
Definitions
Contrast Use Considerations
Contrast administration — document risk/benefit and renal status
Document contrast use decisions carefully: weigh the diagnostic benefit of contrast-enhanced whole-body CT against patient-specific risks and include justification for contrast administration in the record.
- Record baseline renal function and rationale if administering IV contrast for whole‑body CT.
- If contrast is withheld due to renal risk, document alternative imaging strategies.
Contrast risk — balance renal injury risk against diagnostic need
In trauma and other high‑risk patients, explicitly consider and document the risk of contrast-related renal injury when ordering contrast-enhanced whole‑body CT and balance this against the potential diagnostic benefit.
- Assess and record renal function before contrast-enhanced whole‑body CT when clinically feasible.
- Document the clinical rationale if contrast is used despite elevated renal risk.
Services Not Covered
Total-body CT screening (whole-body/full-body) and full-body ultrafast (electron-beam) CT screening for asymptomatic screening purposes are not covered as they are considered experimental and investigational and have not been shown to be effective as screening tests.
Routine direct-to-consumer or general health full-body CT screening in asymptomatic, low-risk individuals is not covered. Evidence reviews recommend that low-risk asymptomatic individuals not undergo total-body imaging because of limited accuracy data, high false-positive rates, lack of demonstrated outcome benefit, and potential harms.
Background and Context
For-profit clinics have promoted ultrafast or total-body CT as a screening test, but no professional organization recommends whole-body CT for population screening of asymptomatic individuals. There are no published controlled trials demonstrating effectiveness of total-body CT as a screening test, and evidence reviews document frequent incidental findings, false positives, radiation exposure risks, and no proven improvement in clinical outcomes.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.